During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after ...

Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the combination.

targeted radiotherapeutic agent -- significantly prolonged progression-free survival compared with standard-of-care ...